Bio Reports
Leucid Bio Reports Proof-of-Concept for LEU011 CAR-T Therapy in Solid Tumours from Ongoing AERIAL Trial
Proof-of-concept established for LEU011 in the treatment of relapsed/refractory solid tumours LEU011 has been well tolerated, with disease control obser...
November 11, 2025 | News
Takeda’s Mezagitamab Shows Sustained Kidney Function and Proteinuria Reduction Through 18-Month Follow-Up in IgA Nephropathy
Phase 1b, Open-Label Study Follow Up Shows Stable Kidney Function (eGFR) in Patients Treated with Investigational Mezagitamab Through Week 96 – 18 ...
November 10, 2025 | News
Phenomix’s MyPhenome Test Validates GLP-1 Response Prediction Across 88,000 Patients
Studies presented at Obesity Week 2025 validate the test's ability to predict weight-loss response to GLP-1 drugs like semaglutide, including in ...
November 05, 2025 | Report
Novartis Review Reveals Fear of Recurrence as a Major Unmet Need in Breast Cancer Survivorship Across Asia Pacific and the Middle East
A new targeted literature review finds the fear of recurrence a major unmet need in breast cancer survivorship, often found to affect at least two in fiv...
October 31, 2025 | Report
WuXi AppTec Reports RMB32.86 Billion Revenue for First Three Quarters of 2025, Up 18.6% Year-on-Year
Q3 Total Revenue: RMB12.06 Billion, Up 15.3% YoY; Revenue from Continuing Operations[1]Reached RMB12.04 Billion, Up 19.7% YoY Q1-Q3 Total Re...
October 27, 2025 | Company results
ACM Biolabs and National Cancer Centre Singapore Report Encouraging Asia-Based Early Clinical Findings for ACM-CpG Nanoparticle Immunotherapy
ACM Biolabs, a clinical-stage biotechnology company developing next-generation nanoparticle-based immunotherapies, announced encouraging early clinica...
October 23, 2025 | News
AdvanCell’s Lead-212 Radioligand Therapy Shows Strong Safety and Efficacy in Phase 1b Trial for Metastatic Prostate Cancer
Results from the TheraPb Phase 1b dose escalation presented at ESMO 2025 show a promising therapeutic index for 212Pb-ADVC001 in patients with metastat...
October 22, 2025 | News
Sanofi’s Efluelda (Fluzone High-Dose) Cuts Influenza Hospitalisations by 31.9% in Adults Aged 65+
Compared to standard-dose influenza vaccines, Efluelda/Fluzone High-Dose demonstrated a reduction in laboratory-confirmed influenza hospitalizations by a...
October 21, 2025 | News
Aurion Biotech Data Supports Advancing High-Dose AURN001 Regenerative Cell Therapy to Phase 3 Trial in 2026
Data strongly supports advancing high dose AURN001 regenerative cell therapy for patients with corneal endothelial disease to pivotal Phase 3 trial in H1...
October 20, 2025 | News
Daiichi Sankyo and AstraZeneca’s DATROWAY Combination Delivers 68.2% Response and 95.5% Disease Control in First-Line Metastatic Urothelial Cancer
A confirmed objective response rate of 68.2% and a disease control rate of 95.5% was observed with Daiichi Sankyo and AstraZeneca’s DATROWAY in c...
October 20, 2025 | News
Merck Presents Longer-Term Phase 3 Data Showing Pimicotinib Achieves 76.2% Objective Response Rate in TGCT
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2% Global Phase 3 MANEUVER study de...
October 20, 2025 | News
Building Trust Through Quality: How QMS Powers Manufacturing Excellence in Life Sciences
Life sciences sector, a robust Quality Management System (QMS) has become the cornerstone of manufacturing excellence. This is especially true for the medi...
October 16, 2025 | Analysis
Building Biopharma Resilience: Cytiva’s Joonho Choi on the Power of Connected Ecosystems
Amid global supply chain disruptions, tightening regulations, and shifting patient needs, biopharma resilience has become both a stra...
October 15, 2025 | Interview
Ascletis’ Denifanstat (ASC40) Achieves Phase III Success in Moderate-to-Severe Acne Vulgaris
Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulga...
October 15, 2025 | News
Most Read
- How Health Systems Are Reshaping Drug Adoption, Partner Models, and Market Access in 2026
- Top 25 Biotech Innovations Redefining Health And Planet In 2025
- The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
- Top 25 Biotech & Biopharma Leaders in Sustainable Innovation, 2025
- China’s Biopharma Dealmaking Surges in H1 2025, Driven by Record Licensing and Oncology Focus
- Chikungunya in China: How a “Forgotten” Arbovirus Found the Perfect Storm
- How Innovation Gaps in Biopharma Raise New Safety Concerns
- Smart Implants and the Future of Musculoskeletal Injury Treatment
- How Ethical Gaps in Psychiatry Could Undermine Biopharma Progress
- The Evolving Landscape of Women’s Health Innovation in the Asia-Pacific
- Using NLP-Driven Decision Support in Emergency Health Assistance
- Taiwan Steps Into the Global Spotlight With a New Cancer Therapy
- The Role of Unique Device Identification (UDI) in Tracing Medical Device Safety
- The Importance of a Patient’s Mental Health During Clinical Trials
Bio Jobs
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Avantor’s New CEO Ligner Aims to Unlock Global Potential and Deliver Shareholder Value
- AstraZeneca Commits $50 Billion to U.S. Expansion by 2030 in Biggest-Ever Global Investment
- Thermo Fisher, SAMRC, and South Africa’s Department of Science and Innovation Launch CATIR to Nurture Next-Gen Scientists
- Cube Biotech Appoints Former Sartorius CEO Dr. Joachim Kreuzburg to Board of Directors
- FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut
- WuXi XDC Completes Mechanical Build of Singapore Bioconjugate Manufacturing Hub
News
Editor Picks
